杨贵妃传媒視頻

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • 杨贵妃传媒視頻 Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • Common Ground
    • Diagnosis: Debt
    • The Body Shops
    • Priced Out
    • Guns, Race, and Profit
    • Broken Rehab
    • Dead Zone
    • Denied
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Medicare Advantage Billing Probe
  • School Vaccine Mandates
  • Weight Loss Drugs Coverage
  • Opioid Settlement Money
  • Abortion Pill Access

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Aug 27 2026 9:06 AM

Full Issue

Pancreatic Cancer Drug Receives FDA Approval

The drug, daraxonrasib, was approved Wednesday and will be sold under the name Rasonque. In clinical trials, patients who were given the drug showed nearly double the average survival time compared with those treated with chemotherapy.

The Food and Drug Administration (FDA) approved on Wednesday a drug that could extend the survival of those with metastatic pancreatic cancer. The drug, called daraxonrasib, will be sold under the brand name Rasonque from Revolution Medicines. The daily pill targets multiple forms of a protein called RAS, which is a main driver of tumor growth. A late-stage clinical trial with 500 patients showed that the median overall survival nearly doubled to more than 13 months versus a median survival of about 6.7 months for those being treated with standard chemotherapy. (Strauss and Kekatos, 8/26)

More news about cancer 鈥

East Bay residents living near the Chevron Richmond Refinery are at a higher risk of developing cancer and other health ailments from exposure to toxic pollutants, according to preliminary findings released Tuesday by the Bay Area Air District. The air district identified the petroleum refinery 鈥 which spans 2,900 acres near Point Richmond 鈥 as a 鈥渇acility with the potential to pose high health impacts,鈥 making it subject to a health risk assessment as required by a district regulation called Rule 11-18. (Brager, 8/26)

A new study has revealed that the amount of sugar consumed during the first two years of life can have lifelong effects. The study, published in PNAS in early August, focused on a group of 64,761 people born in Britain between 1951 and 1956. At the time, sugar and other common foods were rationed to prevent food shortages following World War II. Using data from the UK Biobank study, researchers compared health outcomes among adults who spent their first 1,000 days under sugar restrictions with those of people born after the restrictions were lifted. (Sitz, 8/26)

A personalized cancer vaccine developed by Moderna and Merck has generated widespread enthusiasm since the companies announced last week that it had succeeded in a late-stage trial. If regulators ultimately approve it, the treatment will be a triumph of immunology and cancer biology. But it may also be a triumph of the algorithm. (Mast, Herper and Chen, 8/27)

Almost 80% of patients with early-stage rectal cancer remained surgery-free for a year or longer after treatment with chemoradiation therapy (CRT), a large randomized study showed. (Bankhead, 8/26)

Both men and women can get EMPD, and it鈥檚 often mistaken for a benign rash, such as eczema. Here are the signs to know. (Sweeney, 8/26)

In other pharma and tech updates 鈥

Starting in July, Medicare began allowing eligible beneficiaries to get obesity drugs for $50 a month. Less than two months in, CVS and Walgreens tell NPR they've each filled around 100,000 such prescriptions. The prescriptions were made possible as part of a pilot called the Bridge program. (Lupkin, 8/26)

The FDA expanded the approval of dolutegravir tablets for oral suspension (Tivicay PD) to include newborns with HIV infections younger than 4 weeks of age, the agency announced on Tuesday. (Rudd, 8/26)

Illegal use of the powerful synthetic opioid fentanyl is more than double its use for medical purposes in the United States, a new study has found. More than 7 of 10 people whose urine tested positive for fentanyl had not been prescribed the drug, but were using it illicitly, researchers report in the September issue of the journal eClinicalMedicine. (Thompson, 8/27)

When it comes to predicting heart attacks and strokes, what matters the most: a number, a picture, or both? (Cooney, 8/26)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, August 27
  • Wednesday, August 26
  • Tuesday, August 25
  • Monday, August 24
  • Friday, August 21
  • Thursday, August 20
More Morning Briefings
RSS Feeds
  • 杨贵妃传媒視頻
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

漏 2026 KFF